Browse Prior Art Database

BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR

IP.com Disclosure Number: IPCOM000232207D
Publication Date: 2013-Oct-25
Document File: 11 page(s) / 49K

Publishing Venue

The IP.com Prior Art Database

Abstract

The present disclosure relates to a bilayered tablet comprising: an extended-release layer comprising niacin and a release-retarding agent; and an immediate-release layer comprising an HMG-CoA reductase inhibitor and a melt-processible polymer.

This text was extracted from a Microsoft Word document.
At least one non-text object (such as an image or picture) has been suppressed.
This is the abbreviated version, containing approximately 14% of the total text.

BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR

Abstract
The present disclosure relates to a bilayered tablet comprising: an extended-release layer comprising niacin and a release-retarding agent; and an immediate-release layer comprising an HMG-CoA reductase inhibitor and a melt-processible polymer.

Reported herein is a bilayered tablet comprising an extended-release layer comprising niacin and a release-retarding agent; and an immediate-release layer comprising an HMG-CoA reductase inhibitor and a melt-processible polymer.

Reported herein is a bilayered tablet comprising an extended-release layer comprising niacin and a release-retarding agent; and an immediate-release layer comprising an HMG-CoA reductase inhibitor, a melt-processible polymer, and a plasticizer.

Reported herein is a bilayered tablet comprising an extended-release layer comprising niacin and hydroxypropyl methylcellulose; and an immediate-release layer comprising an HMG-CoA reductase inhibitor and a melt-processible polymer selected from the group comprising copolymer of polyvinyl pyrrolidone and vinyl acetate, polyoxyethylene-polyoxypropylene block copolymer, and polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol.  

Reported herein is a bilayered tablet comprising an extended-release layer comprising niacin and hydroxypropyl methylcellulose; and an immediate-release layer comprising an HMG-CoA reductase inhibitor, a melt-processible polymer selected from the group comprising copolymer of polyvinyl pyrrolidone and vinyl acetate, polyoxyethylene-polyoxypropylene block copolymer, and polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol, and a plasticizer selected from the group comprising copolymer of ethylene oxide and propylene oxide, polyethylene glycol, and macrogolglycerol hydroxystearate.

Also, reported herein is a process for the preparation of a bilayered tablet, the process comprising the steps of:

a)            preparing an extended-release blend or granules comprising niacin and a release-retarding agent;

b)            preparing immediate-release granules comprising an HMG-CoA reductase inhibitor and a melt-processible polymer; and

c)            compressing the extended-release blend or granules of step a) and immediate-release granules of step b) into a bilayered tablet.

Further, reported herein is a process for the preparation of a bilayered tablet, the process comprising the steps of:

a)            blending niacin and hydroxypropylmethyl cellulose;

b)            optionally, granulating the blend of step a) to obtain extended-release granules;

c)            blending an HMG-CoA reductase inhibitor; a melt-processible polymer selected from the group comprising copolymer of polyvinyl pyrrolidone and vinyl acetate, polyoxyethylene-polyoxypropylene block copolymer, and polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol; optionally a plasticizer selected from the group comprising copolymer of ethylene oxide and propylene oxide; polyethylene glycol; and macrogolglycerol hydroxystearate;

d)           ...